Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)

Model scores of the 29,894 trials active now.

Model score 16% for any early termination, 1% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 16% of the time (1,938 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2023-07-05. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: celldose ofchemotherapyand neckhead and
  Phrases that lowered it: participantsparticipantlaboratoryprostateinvestigator
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 1 (lowers risk) · Design
• Sponsor's past trials: 2265 (raises risk) · Sponsor's track record
• Sponsor's past termination rate: 5.8% (lowers risk) · Sponsor's track record
• Disease area, cancer: Yes (raises risk) · Disease area
• Maximum age: 93 (lowers risk) · Who can join
• Drug's FAERS reports with a death: 23.1% (raises risk) · Drug's FDA history
• Drug's FAERS reports marked serious: 94.7% (raises risk) · Drug's FDA history
• Number of arms: 9 (lowers risk) · Design
• Drug's FAERS reports before start: 159727 (lowers risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Has a data monitoring committee: No (lowers risk) · Design
• Trials the sponsor started in the prior 2 years: 227 (lowers risk) · Sponsor's track record
• Collaborators: 1 (raises risk) · Design
• Responsible party: sponsor (lowers risk) · Design
• Drug's FAERS reports in the prior 12 months: 31013 (lowers risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Study of a Combination of GSK1795091 and Immunotherapies in Subjects With Advanced Solid Tumors NCT03447314 · started 2018 · scored riskier than 64% of active trials completed
• GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors NCT03693612 · started 2018 · scored riskier than 66% of active trials completed
• A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors NCT02452424 · started 2015 · scored riskier than 88% of active trials terminated
• Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants NCT04939701 · started 2021 · scored riskier than 62% of active trials terminated
• A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and Cemiplimab in Patients With Advanced Solid Tumors NCT03192345 · started 2017 · scored riskier than 39% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.